Cover Image

Tysabri(克隆氏症)- 預測與市場分析

Tysabri (Crohn's Disease) - Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 297509
出版日期 內容資訊 英文 47 Pages
Back to Top
Tysabri(克隆氏症)- 預測與市場分析 Tysabri (Crohn's Disease) - Forecast and Market Analysis to 2022
出版日期: 2014年01月31日 內容資訊: 英文 47 Pages





第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
  • 症狀
  • 預測
  • QOL

第4章 疾病的管理

  • 治療概要

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估

第6章 Tysabri(natalizumab)

  • 概要
  • 功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄


Product Code: GDHC329DFR

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Tysabri (natalizumab), which was discovered by Elan, is a recombinant humanized immunoglobulin G4 (IgG4) mAb that acts as a selective α-4 integrin inhibitor. It binds to the α4-subunit of α4ß1 and α4ß7 integrins expressed on the surface of leukocytes and inhibits their α4-mediated adhesion to mucosal VCAM-1 and MadCAM-1 receptors, respectively. Disruption of these molecular interactions prevents transmigration of leukocytes across the endothelium into inflamed tissue. Tysabri was initially approved for the treatment of MS, and gained approval in the US in 2008 for use in CD as a second-line therapy.


  • Overview of Crohn's disease (CD), including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Tysabri including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Tysabri for the top six countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain and China

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Crohn's disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Tysabri performance
  • Obtain sales forecast for Tysabri from 2012-2022 in top six countries (the US, France, Germany, Italy, Spain and China)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Disease Management

  • 4.1. Treatment Overview

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Tysabri (natalizumab)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed CD Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in This Study
  • 7.6. Primary Research - Prescriber Survey
  • 7.7. About the Authors
    • 7.7.1. Author/Reviewer
    • 7.7.2. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

1 List of Tables

  • Table 1: Symptoms of CD
  • Table 2: Treatment Guidelines for CD
  • Table 3: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013
  • Table 4: Leading Branded Drugs Used to Treat CD
  • Table 5: Product Profile - Tysabri
  • Table 6: Tysabri SWOT Analysis, 2013
  • Table 7: Global Sales Forecasts ($) for Tysabri, 2012-2022
  • Table 8: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right)
  • Figure 2: Potential Biologic Drug Targets for CD
  • Figure 3: Patient Care Path for CD
Back to Top